LRRK2 siRNA therapy (Argo Biopharma)

N/A

Report date: 2026/01/08 11:08:08
NME

Base Information

Drug NameLRRK2 siRNA therapy (Argo Biopharma)
Drug Alias NameN/A
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionLeucine-rich repeat serine/threonine-protein kinase 2 modulators
TargetsLeucine-rich repeat serine/threonine-protein kinase 2
Therapy Area/IndicationsParkinson Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesShanghai Argo Biopharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Argo Biopharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsParkinson Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A